Non-Human Primate (NHP) Model Service for Cell Therapy (CAR-T/iPSC) Efficacy Study

Are you currently facing complex challenges in cell and gene therapy, such as unpredictable toxicity profiles, limited translatability from rodent models, or the need for a more clinically predictive preclinical phase? Creative Biolabs' NHP Cell Therapy Models offer a robust and clinically relevant solution. Our services help you accelerate drug development and obtain critical safety and efficacy data by leveraging our advanced NHP platforms, bridging the gap between discovery and clinical trials.

Introduction of NHP Cell Therapy Models

What Our Service Is

Creative Biolabs' NHP Cell Therapy Models provide a comprehensive preclinical platform for the in vivo evaluation of advanced therapeutics, including CAR-T cell and iPSC-derived cell therapies. This service allows for the assessment of crucial parameters such as safety, biodistribution, persistence, and efficacy in a biological system that closely mimics human physiology and immune responses. Our services are specifically designed for:

• Safety and Toxicity Profiling: Assessing potential on-target/off-tumor toxicities and cytokine-driven systemic effects of CAR-T cell therapies in a clinically relevant context.
• Efficacy and Engraftment Studies: Evaluating the long-term survival, functional integration, and therapeutic potential of iPSC-derived cells, such as dopaminergic neurons or cardiomyocytes, in a large animal model.
• Immunogenicity Assessment: Directly comparing autologous versus allogeneic cell transplantation to understand and mitigate host immune rejection, a critical barrier for iPSC-based therapies.

Why Choose Us?

While murine models have long been the industry standard for early-stage research, they often fail to accurately predict human responses, particularly in complex areas like systemic toxicity and immune-mediated rejection. Creative Biolabs' NHP models overcome these limitations. With genetic and immunological similarities to humans, NHPs provide a higher predictive value for both the potency and safety of novel cell therapies, as shown by published data. By choosing our NHP models, you gain a clear, reliable pathway to de-risk your clinical translation and gain confidence in your therapeutic candidates.

Fig.1 Autologous versus allogeneic transplantation of iPSC-derived neural cells in a NHP's brain.¹

Key Benefits of Our Service

Our NHP Cell Therapy Models are distinguished by unique features that are critical for success in your project. We provide a platform that is not only scientifically rigorous but also highly adaptable to your specific needs.

• Responsiveness and Speed: We understand that time is of the essence in drug development. Our streamlined project initiation and execution protocols ensure a rapid turnaround for your studies, from initial consultation to final data delivery.
• Extensive NHP Resources: Our access to a diverse and well-characterized colony of Cynomolgus monkey and other NHPs allows us to select the most appropriate models for your research, including those with defined genetic backgrounds for allogeneic studies.
• Customization and Flexibility: Our protocols are not one-size-fits-all. We work closely with you to design a study that meets your specific requirements, from customized lymphodepletion regimens for CAR-T studies to specialized surgical techniques for iPSC transplantation.
• In-Depth Reporting: Our final reports are comprehensive, providing not only raw data but also detailed analysis, histological evaluations, and expert interpretation to help you make informed decisions. We go beyond simple observation, delivering insights into toxicity mechanisms and graft-host interactions.

How Creative Biolabs' Service Can Assist Your Project?

Our NHP models provide a powerful tool to address key challenges and validate your therapeutic strategy. We offer clear deliverables and problem-solving capabilities to ensure a smooth transition from preclinical to clinical development.

Key Deliverables

• Detailed laboratory reports with expert analysis
• Raw data files (e.g., flow cytometry, qPCR, ELISA)
• Annotated pathology slides and histological images
• Pharmacokinetic (PK) and pharmacodynamic (PD) data
• Cell persistence and biodistribution profiles

Capabilities & Partnerships

Service-Specific Data

• Annual Sample Size: Over 50,000 samples analyzed per year.
• Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
• Study Pass Rate: 99%+ success rate in meeting study endpoints.

Our Valued Partners

Frequently Asked Questions

Contact Us

Creative Biolabs' NHP Cell Therapy Models provide an essential and highly predictive preclinical platform for the development of advanced therapeutics. By leveraging our deep expertise and robust resources, we help you overcome the limitations of traditional models, enabling confident decisions and accelerating your journey from the bench to the clinic. To learn more about how our NHP Cell Therapy Models can advance your project, we invite you to connect with our team of experts.